Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical implications of the competitive inhibition of the debrisoquin-metabolizing isozyme by quinidine.

Archives of internal medicine - 1 Oct 1991

Caporaso N E, Shaw G L

Abstract excerpt

Approximately 10% of western populations are genetically deficient in the enzyme that metabolizes the antihypertensive drug debrisoquin. These "poor metabolizers" process many common medications in an aberrant fashion, resulting in a variety of untoward consequences including exaggerated drug effect, subtherapeutic drug concentrations, or complex drug interactions. A variety of medications, including...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Cytochrome P-450 CYP2D6
Share to Cytochrome P-450 Enzyme Inhibitors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cytochrome P-450 Enzyme System

Share to Drug Interactions

Share to Mixed Function Oxygenases

Share to Phenotype

Share to Quinidine

Source

Identifiers

PMID: 1681790

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical implications of the competitive inhibition of the debrisoquin-metabolizing isozyme by quinidine.PMID 1681790Read ↗

Genetically determined adverse drug reactions involving metabolism.Semantic proximity Read ↗

Comparative effects of the diastereoisomers, quinine and quinidine in producing phenocopy debrisoquine poor metabolisers (PMs) in healthy volunteers.Semantic proximity Read ↗

The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.Semantic proximity Read ↗

Clinical consequences of polymorphic drug oxidation.Semantic proximity Read ↗

[Pharmacogenetics of antidepressant metabolism. Value of the debrisoquin test].Semantic proximity Read ↗

Pharmacogenetics of Debrisoquine and its Use as a Marker For CYP2D6 Hydroxylation CapacitySemantic proximity Read ↗

A protocol for the safe administration of debrisoquine in biochemical epidemiologic research protocols for hospitalized patients.Semantic proximity Read ↗

Polymorphic debrisoquin metabolism in a Turkish population.Semantic proximity Read ↗

Debrisoquine phenotype and the pharmacokinetics and beta-2 receptor pharmacodynamics of metoprolol and its enantiomers.Semantic proximity Read ↗

The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation.Semantic proximity Read ↗

Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin.Semantic proximity Read ↗

Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.